Pharmaceuticals, Biotechnology and Life Sciences
SkinBioTherapeutics, a life science company focused on skin health, has agreed an eight month extension to its research contract with the University of Manchester to June 2018.
Oxford BioDynamics, a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has entered into a development agreement with two pharmaceutical companies, that are collaborating on an anti PD-L1 therapy.
AstraZeneca has reported top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that compared the effect of once-weekly Bydureon (exenatide extended-release) versus placebo, when added to usual type-2 diabetes care, on the risk of MACE, a composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes (T2D) at a wide range of CV risk.
Novartis’ head-to-head FLAME study suggest that inhaled corticosteroids (ICS) may not be needed in some chronic obstructive pulmonary disease (COPD) patients with high blood eosinophil (a type of white blood cell) counts.
AstraZeneca has entered into an agreement with Recordati S.p.A for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe.
InnovaDerma, a UK developer of life sciences, will launch a new haircare product range and its entry into the UK skincare market.
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, has announced new preclinical data for ANAVEX 2-73 in the neurodevelopmental disorders Angelman syndrome, Fragile X syndrome and Rett syndrome.
Celgene Corporation has announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex).
Arix Bioscience on Friday said that its new business group, Iterum, has raised $65 million by closing a Series B investment round. “Arix is delighted to have led this $65m funding round comprising many of the biotech sector’s leading specialist investors,” said…
The Saudi Food & Drug Authority (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.